STEMvision™ Automated and Standardized CFC Enumeration
Features and benefits of the STEMvision™ system, the world's first automated instrument and computer system for imaging and scoring hematopoietic colonies in the colony-forming cell (CFC) assay
Limitless Potential: Do More with TeSR™
mTeSR™1 is a highly specialized and defined, serum-free and complete cell culture medium, with established protocols for applications ranging from gene editing, bioreactor expansion, to lineage-specific differentiation
Optimization of ALDEFLUOR™ Protocol
Learn how STEMCELL Technologies' scientists doubled the signal strength in mammary epithelial cells with a few simple protocol modifications using ALDEFLUOR™ to detect Aldehyde Dehydrogenase bright (ALDHbr) cells
How to Effectively Communicate Your Science to the Public
Watch this webinar to learn how to use blogs and social media channels to inform the public about your scientific discoveries, with STEMCELL Technologies' Kristina McBurney, Senior Manager, Scientific Communications; and Leanna Bedell, Manager, Social Media.
Re-Creating Disease with Kidney Organoids and CRISPR
In this webinar, Dr. Benjamin Freedman from the University of Washington provides an overview of re-creating disease using kidney organoids and CRISPR-Cas9 genome editing. As a postdoctoral fellow in the Renal Division at Brigham and Women’s Hospital at Harvard Medical School, Dr. Freedman was responsible for several innovative techniques that he describes in this webinar, including differentiation of human pluripotent stem cells (hPSCs) into kidney organoids containing nephron-like segments and generating knockout mutations in organoids with CRISPR.
EasySep™小鼠TIL（CD45）正选试剂盒
STEMvision™ Automated and Standardized CFC Enumeration Features and benefits of the STEMvision™ system, the world's first automated instrument and computer system for imaging and scoring hematopoietic colonies in the colony-forming cell (CFC) assay
STEMCELL Technologies Inc. Corporate Overview This video is an overview of STEMCELL Technologies Inc, a privately owned biotechnology company that develops specialty cell culture media
STEMdiff™: Products for Differentiating Human Pluripotent Stem Cells Learn about two new products, specifically optimized for the differentiation of human pluripotent stem cells, STEMdiff™ APEL™ Medium and STEMdiff™ Neural Induction Medium
Why Use Semi-Solid Medium for Cloning Hybridomas and CHO Cells Cloning hybridomas and CHO cells can be done faster and more efficiently using semi-solid cloning, compared to traditional cloning techniques
Limitless Potential: Do More with TeSR™ mTeSR™1 is a highly specialized and defined, serum-free and complete cell culture medium, with established protocols for applications ranging from gene editing, bioreactor expansion, to lineage-specific differentiation
Optimization of ALDEFLUOR™ Protocol Learn how STEMCELL Technologies' scientists doubled the signal strength in mammary epithelial cells with a few simple protocol modifications using ALDEFLUOR™ to detect Aldehyde Dehydrogenase bright (ALDHbr) cells
How to Effectively Communicate Your Science to the Public Watch this webinar to learn how to use blogs and social media channels to inform the public about your scientific discoveries, with STEMCELL Technologies' Kristina McBurney, Senior Manager, Scientific Communications; and Leanna Bedell, Manager, Social Media.
How to Perform Semi-Solid Cloning of CHO Cell Lines in 96-Well Plates Using ClonaCell™-CHO Medium This video outlines the ClonaCell™-CHO 96-well plate semi-solid cloning protocol, including plating, liquid overlay, screening, and colony picking
Re-Creating Disease with Kidney Organoids and CRISPR In this webinar, Dr. Benjamin Freedman from the University of Washington provides an overview of re-creating disease using kidney organoids and CRISPR-Cas9 genome editing. As a postdoctoral fellow in the Renal Division at Brigham and Women’s Hospital at Harvard Medical School, Dr. Freedman was responsible for several innovative techniques that he describes in this webinar, including differentiation of human pluripotent stem cells (hPSCs) into kidney organoids containing nephron-like segments and generating knockout mutations in organoids with CRISPR.
